Review
doi: 10.1007/s11912-010-0144-x.
Incorporation of Biomarker Assessment in Novel Clinical Trial Designs: Personalizing Brain Tumor Treatments
Affiliations
- PMID: 21125354
- PMCID: PMC3155285
- DOI: 10.1007/s11912-010-0144-x
Item in Clipboard
Review
Incorporation of Biomarker Assessment in Novel Clinical Trial Designs: Personalizing Brain Tumor Treatments
Curr Oncol Rep.
.
Free PMC article
Abstract
Advances in molecular genetics have aided the identification of potential biomarkers with significant clinical promise in neurooncology. These advances and the evolution of targeted therapeutics necessitate the development and incorporation of innovative clinical trial designs that can effectively validate and assess the clinical utility of biomarkers. In this article, we review the use and potential of several such designs in neurooncology trials in order to support the development of personalized treatment approaches for brain tumor patients.
Similar articles
-
Reinventing clinical trials: a review of innovative biomarker trial designs in cancer therapies.Br Med Bull. 2015 Jun;114(1):17-27. doi: 10.1093/bmb/ldv011. Epub 2015 Apr 28. Br Med Bull. 2015. PMID: 25921239 Review.
-
Biomarker-based trials in neuro-oncology.Chin Clin Oncol. 2015 Sep;4(3):38. doi: 10.3978/j.issn.2304-3865.2015.09.04. Chin Clin Oncol. 2015. PMID: 26408305 Review.
-
Incorporation of prognostic and predictive factors into glioma clinical trials.Curr Oncol Rep. 2013 Feb;15(1):56-63. doi: 10.1007/s11912-012-0279-z. Curr Oncol Rep. 2013. PMID: 23125011 Free PMC article. Review.
-
Personalized Medicine: Genomics Trials in Oncology.Trans Am Clin Climatol Assoc. 2015;126:133-43. Trans Am Clin Climatol Assoc. 2015. PMID: 26330667 Free PMC article. Review.
-
New clinical trial designs in the era of precision medicine: An overview of definitions, strengths, weaknesses, and current use in oncology.Cancer Treat Rev. 2019 Feb;73:20-30. doi: 10.1016/j.ctrv.2018.12.003. Epub 2018 Dec 11. Cancer Treat Rev. 2019. PMID: 30572165 Review.
Cited by 9 articles
-
BICD1 expression, as a potential biomarker for prognosis and predicting response to therapy in patients with glioblastomas.Oncotarget. 2017 Nov 27;8(69):113766-113791. doi: 10.18632/oncotarget.22667. eCollection 2017 Dec 26. Oncotarget. 2017. PMID: 29371945 Free PMC article.
-
Biomarker-Guided Non-Adaptive Trial Designs in Phase II and Phase III: A Methodological Review.J Pers Med. 2017 Jan 25;7(1):1. doi: 10.3390/jpm7010001. J Pers Med. 2017. PMID: 28125057 Free PMC article. Review.
-
IQGAP1 in Podosomes/Invadosomes Is Involved in the Progression of Glioblastoma Multiforme Depending on the Tumor Status.Int J Mol Sci. 2017 Jan 13;18(1):150. doi: 10.3390/ijms18010150. Int J Mol Sci. 2017. PMID: 28098764 Free PMC article.
-
Biomarker-Guided Adaptive Trial Designs in Phase II and Phase III: A Methodological Review.PLoS One. 2016 Feb 24;11(2):e0149803. doi: 10.1371/journal.pone.0149803. eCollection 2016. PLoS One. 2016. PMID: 26910238 Free PMC article. Review.
-
Current Challenges in Glioblastoma: Intratumour Heterogeneity, Residual Disease, and Models to Predict Disease Recurrence.Front Oncol. 2015 Nov 16;5:251. doi: 10.3389/fonc.2015.00251. eCollection 2015. Front Oncol. 2015. PMID: 26636033 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grant support
LinkOut - more resources
Full Text Sources
Medical
